Internal Medicine, Medical Oncology · Huntsville, AL
NPI
1790765337
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3601 Cci Dr NW
Huntsville, AL, 35805
Phone (256) 705-4224
Groups this clinician bills Medicare through
Medicare paid, 2024
$13.0M
608,879 services
Medicare patients, 2024
1,925
Average age 75
Drug cost, 2024
$9.2M
5,506 prescriptions
Company payments, 2025
$8,482
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John Waples was code J9271 (injection, pembrolizumab, 1 mg), 73,600 times for 49 patients. In total John Waples billed 608,879 services in 245 codes, and Medicare paid $13.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-09-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 73,600 | 49 | $44.60 | $3.3M |
| J0642 Injection, levoleucovorin (khapzory), 0.5 mg | Office | 54,250 | 13 | $1.25 | $68K |
| J9299 Injection, nivolumab, 1 mg | Office | 52,620 | 24 | $24.60 | $1.3M |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 49,515 | 36 | $2.31 | $114K |
| J0897 Injection, denosumab, 1 mg | Office | 45,840 | 261 | $20.34 | $932K |
| J0185 Injection, aprepitant, 1 mg | Office | 19,110 | 30 | $1.32 | $25K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 15,120 | 14 | $39.28 | $594K |
| J9267 Injection, paclitaxel, 1 mg | Office | 14,370 | 23 | $0.08 | $1,162 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 14,330 | 37 | $36.88 | $528K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 11,500 | 104 | $15.58 | $179K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 10,300 | 11 | $0.06 | $579 |
| J1930 Injection, lanreotide, 1 mg | Office | 10,080 | 17 | $37.89 | $382K |
| J9173 Injection, durvalumab, 10 mg | Office | 7,280 | 11 | $63.77 | $464K |
| J9071 Injection, cyclophosphamide (auromedics), 5 mg | Office | 7,116 | 11 | $1.25 | $8,914 |
| Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Office | 6,670 | 20 | $51.77 | $345K |
By year: 2022 $10.9M for 615,741 services; 2023 $12.4M for 678,504 services; 2024 $13.0M for 608,879 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 5,160 | 1,717 | $7.54 | $39K |
| 80053 Clinical Chemistry | 5,070 | 1,707 | $10.26 | $52K |
| 36415 Venipuncture Blood Collection | 4,768 | 1,682 | $8.64 | $41K |
| 83735 Clinical Chemistry | 2,137 | 766 | $6.53 | $14K |
| 84443 Clinical Chemistry | 1,683 | 736 | $16.46 | $28K |
| 83540 Clinical Chemistry | 1,593 | 935 | $6.27 | $9,981 |
| 83550 Clinical Chemistry | 1,593 | 935 | $8.46 | $13K |
| 82728 Clinical Chemistry | 1,590 | 938 | $13.18 | $21K |
| 82607 Clinical Chemistry | 1,362 | 896 | $14.56 | $20K |
| 84439 Clinical Chemistry | 1,349 | 718 | $8.77 | $12K |
Medicare prescription drug claims, 2024
In 2024, the drug John Waples prescribed most often to Medicare patients was Eliquis (Apixaban), with 318 prescriptions and refills. In total John Waples wrote 5,506 Medicare prescriptions that cost $9.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 318 | 487 | 99 | $275K |
| Anastrozole Generic | 318 | 889 | 125 | $8,719 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 242 | 242 | 70 | $7,152 |
| Xarelto Rivaroxaban | 215 | 346 | 49 | $188K |
| Potassium Chloride Generic | 194 | 270 | 72 | $3,543 |
| Meloxicam Generic | 151 | 263 | 54 | $632 |
| Levothyroxine Sodium Generic | 138 | 289 | 48 | $1,211 |
| Zolpidem Tartrate Generic | 133 | 150 | 31 | $876 |
| Gabapentin Generic | 128 | 145 | 39 | $1,578 |
| Omeprazole Generic | 116 | 250 | 45 | $1,545 |
| Ondansetron Odt Ondansetron | 114 | 116 | 67 | $3,312 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 113 | 113 | 77 | $1,331 |
| Dexamethasone Generic | 104 | 116 | 27 | $962 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 100 | 100 | 17 | $2,584 |
| Xtandi Enzalutamide | 96 | 96 | 17 | $1.2M |
Brand drugs: 1,479 claims; generic drugs: 4,013 claims; opioid claims: 640.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John Waples $8,482 ($8,482 in general payments such as food, travel and fees) from 33 companies. The largest payer was Kyowa Kirin, Inc. with $3,900.
| Company | Payments | Amount |
|---|---|---|
| Kyowa Kirin, Inc. 4151.T | 1 | $3,900 |
| Pfizer Inc. PFE | 6 | $1,474 |
| Genzyme Corporation SNY | 3 | $408 |
| GlaxoSmithKline, LLC. GSK | 3 | $292 |
| Blueprint Medicines Corporation SNY | 2 | $218 |
| Geron Corporation GERN | 2 | $195 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $166 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $162 |
| BeiGene USA, Inc. ONC | 2 | $159 |
| Genmab U.S., Inc. GMAB | 2 | $158 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.